Davidsson L, Lönnerdal B, Sandström B, Kunz C, Keen C L
Department of Clinical Nutrition, University of Gothenburg, Sahlgrenska Hospital, Sweden.
J Nutr. 1989 Oct;119(10):1461-4. doi: 10.1093/jn/119.10.1461.
It is known that the metabolic handling of manganese (Mn) introduced via the diet or by intravenous injection is quite different. We hypothesized that this difference could be due in part to different proteins carrying Mn in plasma that could affect tissue uptake and retention. To test this idea, 54Mn was administered orally or intravenously to rats, and blood samples were taken by cardiac puncture at various time points postdosing. Plasma proteins were separated using fast protein liquid chromatography with a combination of anion exchange and gel filtration columns. Using these methods, independent of the route of 54Mn administration, transferrin was identified as the major Mn-binding protein in plasma. The identity was further confirmed by SDS-polyacrylamide gradient gel electrophoresis and Western blotting. These results conclusively show that 54Mn in plasma is carried by transferrin, regardless of route of administration and time postdosing.
众所周知,通过饮食或静脉注射引入的锰(Mn)的代谢处理方式有很大不同。我们推测,这种差异可能部分归因于血浆中携带锰的不同蛋白质,这些蛋白质可能会影响组织对锰的摄取和保留。为了验证这一想法,给大鼠口服或静脉注射54Mn,并在给药后的不同时间点通过心脏穿刺采集血样。使用阴离子交换和凝胶过滤柱相结合的快速蛋白质液相色谱法分离血浆蛋白。通过这些方法,无论54Mn的给药途径如何,转铁蛋白都被确定为血浆中主要的锰结合蛋白。通过SDS-聚丙烯酰胺梯度凝胶电泳和蛋白质免疫印迹法进一步证实了其身份。这些结果确凿地表明,无论给药途径和给药后时间如何,血浆中的54Mn都是由转铁蛋白携带的。